Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sho Sakui

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|August 19, 2024
Principal quantile treatment effect estimation using principal scoresKotaro Mizuma, Takamasa Hashimoto, Sho Sakui, et al.
Vaccine|December 21, 2023
Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trialKenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, et al.
Vaccine|August 3, 2025
One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trialKenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, et al.
Vaccine|February 18, 2022
A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim reportTaisei Masuda, Kyoko Murakami, Kenkichi Sugiura, et al.
Vaccine|May 2, 2022
Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trialTaisei Masuda, Kyoko Murakami, Kenkichi Sugiura, et al.
Vaccine|May 17, 2023
Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trialKenji Kuriyama, Kyoko Murakami, Taisei Masuda, et al.
Vaccine|February 3, 2024
One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trialKenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, et al.
Pediatrics International : Official Journal of the Japan Pediatric Society|December 27, 2025
Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label studyKouji Masumoto, Mitsuru Muto, Takato Sasaki, et al.
Expert Opinion on Drug Safety|June 30, 2022
Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)Tamio Teramoto, Hisao Ogawa, Hirotsugu Ueshima, et al.
Journal of Pediatric Gastroenterology and Nutrition|June 26, 2023
Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral SupportMasahiro Chiba, Kouji Masumoto, Tatsuru Kaji, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|August 19, 2024
Principal quantile treatment effect estimation using principal scoresKotaro Mizuma, Takamasa Hashimoto, Sho Sakui, et al.
Vaccine|December 21, 2023
Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trialKenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, et al.
Vaccine|August 3, 2025
One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trialKenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, et al.
Vaccine|February 18, 2022
A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim reportTaisei Masuda, Kyoko Murakami, Kenkichi Sugiura, et al.
Vaccine|May 2, 2022
Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trialTaisei Masuda, Kyoko Murakami, Kenkichi Sugiura, et al.
Vaccine|May 17, 2023
Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trialKenji Kuriyama, Kyoko Murakami, Taisei Masuda, et al.
Vaccine|February 3, 2024
One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trialKenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, et al.
Pediatrics International : Official Journal of the Japan Pediatric Society|December 27, 2025
Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label studyKouji Masumoto, Mitsuru Muto, Takato Sasaki, et al.
Expert Opinion on Drug Safety|June 30, 2022
Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)Tamio Teramoto, Hisao Ogawa, Hirotsugu Ueshima, et al.
Journal of Pediatric Gastroenterology and Nutrition|June 26, 2023
Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral SupportMasahiro Chiba, Kouji Masumoto, Tatsuru Kaji, et al.
Pageof 1